Trial Profile

A Combination Proof-of-Concept Phase 2 Clinical Trial of AB-729 in Combination with AB-506 in Subjects with Chronic Hepatitis B

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 11 Oct 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Oct 2019 According to an Arbutus Biopharma media release, the company announced to discontinue the clinical development of AB-506 due to two cases of acute hepatitis in phase 1a portion of the trial ACTRN12618000987268.
03 Oct 2019 Status changed from planning to withdrawn prior to enrolment, according to an Arbutus Biopharma media release.
05 Aug 2019 According to an Arbutus Biopharma media release, the company anticipate moving into this combination proof-of-concept phase 2 clinical trial in subjects with chronic hepatitis B in the second half of 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com